

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Embden et al.

Serial No.: To be assigned

Filed: December 1, 2003

For: METHODS AND MEANS FOR
PREVENTING OR TREATING
INFLAMMATION OR PRURITUS

Examiner: To be assigned

Group Art Unit: To be assigned

Attorney Docket No.: 2183-6192US

NOTICE OF EXPRESS MAILING

Express Mail Mailing Label Number: EV325784174US

Date of Deposit with USPS: December 1, 2003

Person making Deposit: Christopher Haughton

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 or PTO/SB/08 be considered by the Examiner and made of record. Copies of the listed documents are enclosed pursuant to 37 C.F.R. § 1.98(a).

In accordance with 37 C.F.R. § 1.97(g) and (h), filing of this Information Disclosure Statement is not to be construed as a representation that a search has been made or an admission that the information cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b). Further, no representation is made by Applicants herein that no other possible material information as defined in 37 C.F.R. § 1.56(b) exists.

Pursuant to 37 C.F.R. § 1.98(d), a copy of any patent, publication or other information listed in the Information Disclosure Statement is not required to be provided if it was previously cited by or submitted to the office in a prior application, provided that the prior application is properly identified in the statement and relied upon for an earlier filing date under 35 U.S.C. § 120.

Accordingly, no copy of information marked with a pound sign (#) is enclosed because it was previously cited or submitted to the patent office in a prior application which is properly identified above, and is relied upon for an earlier filing date. The references are as follows:

U.S. Patent Documents

<u>U.S. Patent No.</u>	<u>Publication Date</u>	<u>Patentee</u>
#US - 5,614,198	3/1997	Kennedy et al.
#US - 4,906,457	3/1990	Ryan et al.
#US - 3,950,509	4/1976	Gerks et al.

Foreign Patent Documents

<u>Document No.</u>	<u>Publication Date</u>	<u>Country</u>
#0 564 307 A1	10/1993	Europe
#06025000	01/1994	Japan
#WO 95/12408	05/1995	PCT
#WO 97/04792	02/1997	PCT
#2 311 727 A	10/1997	United Kingdom

Other Documents

#Notification of Transmittal of the International Preliminary Examination Report.

#GENELL et al., Protease Inhibitors in Plasma and Faecal Extracts from Patients with Active Inflammatory Bowel Disease, June 1986, pp. 598-604.

#HUTTON et al., Mucolysis of the colonic mucus barrier by faecal proteinases: inhibition by interacting polyacrylate, March 1990, pp. 265-271.

Attorney Docket No.: 2183-6192US

#FRENKEL et al., Chymotrypsin-specific protease inhibitors decrease H₂O₂ formation by activated human polymorphonuclear leukocytes, September 1987, pp. 1207-1212.

#KEILOVA et al., Naturally occurring inhibitors of intracellular proteinases, 1977, pp. 1873-1881.

#YAHAGI et al., Manufacture of soybean extracts containing trypsin inhibitors for controlling skin disorders, July 8, 1997, Abstract No. 127:126636.

#PEARCE et al., Archives of Biochemistry and Biophysics, February 1982, Vol. 213, No. 2, pp. 456-62.

#RODIS et al., Plant Physiol., 1984, Vol. 74, pp. 907-11.

#RADOEV et al., Nauchni Tr., Vissh Inst. Khranitelna Vkusova Prom. Plovdiv, 1964, Vol. 11, pp. 265-70.

#WOROWSKI et al., Acta Pol. Pharm., 1973, Vol. 30, No. 4, pp. 453-57.

#Pursuant to 37 C.F.R. § 1.98(d), copies of the previously identified patents are not being provided since they were previously cited by or submitted to the Office in the following prior application:

Serial No.: 09/716,612

Filed: November 20, 2000

For: METHODS AND MEANS FOR PREVENTING OR TREATING INFLAMMATION OR PRURITIS, which application is being relied upon for an earlier filing date under 35 U.S.C. § 120.

In compliance with the duty to disclose information material to patentability pursuant to 37 C.F.R. § 1.56, Applicants hereby identify the following listed copending applications naming a common inventor:

Attorney Docket No.: 2183-4616US

Serial No.: 09/716,612

Filing Date: 11/20/2000

Title: METHODS AND MEANS FOR PREVENTING OR TREATING
INFLAMMATION OR PRURITIS

Attorney Docket No.: 2183-6192US

This Information Disclosure Statement is filed within three (3) months of the filing date of the above-identified application, and no certification pursuant to 37 C.F.R. § 1.97(c) or a fee pursuant to 37 C.F.R. § 1.17(p) is required.

Respectfully submitted,



Allen C. Turner

Registration No. 33,041

Attorney for Applicant(s)

TRASKBRITT, P.C.

P.O. Box 2550

Salt Lake City, Utah 84110-2550

Telephone: 801-532-1922

Date: November 18, 2003

ACT/bv

Enclosures: Form PTO-1449 or PTO/SB/08

Cited Documents

Document in ProLaw

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

U.S. PATENT DOCUMENTS[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Country	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
		#0 564 307 A1	10/1993	Europe		
		#06025000	01/1994	Japan		
		#WO 95/12408	05/1995	PCT		
		#WO 97/04792	02/1997	PCT		
		#2 311 727 A	10/1997	United Kindgom		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	To be assigned
Filing Date	December 1, 2003
First Named Inventor	Embden et al.
Group Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	2183-6192IIS

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		#Notification of Transmittal of the International Preliminary Examination Report.	
		#GENELL et al., Protease Inhibitors in Plasma and Faecal Extracts from Patients with Active Inflammatory Bowel Disease, June 1986, pp. 598-604.	
		#HUTTON et al., Mucolysis of the colonic mucus barrier by faecal proteinases: inhibition by interacting polyacrylate, March 1990, pp. 265-271.	
		#FRENKEL et al., Chymotrypsin-specific protease inhibitors decrease H2O2 formation by activated human polymorphonuclear leukocytes, September 1987, pp. 1207-1212.	
		#KEILOVA et al., Naturally occurring inhibitors of intracellular proteinases, 1977, pp. 1873-1881.	
		#YAHAGI et al., Manufacture of soybean extracts containing trypsin inhibitors for controlling skin disorders, July 8, 1997, Abstract No. 127:126636.	
		#PEARCE et al., Archives of Biochemistry and Biophysics, February 1982, Vol. 213, No. 2, pp. 456-62.	
		#RODIS et al., Plant Physiol., 1984, Vol. 74, pp. 907-11.	
		#RADOEV et al., Nauchni Tr., Vissh Inst. Khranitelna Vkusova Prom. Plovdiv, 1964, Vol. 11, pp. 265-70.	
		#WOROWSKI et al., Acta Pol. Pharm., 1973, Vol. 30, No. 4, pp. 453-57.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

#Pursuant to 37 C.F.R. § 1.98(d), copies of the previously identified patents are not being provided since they were previously cited by or submitted to the Office in the following prior application:

Serial No.: 09/716,612

Filed: November 20, 2000

For: METHODS AND MEANS FOR PREVENTING OR TREATING INFLAMMATION OR PRURITIS, which application is being relied upon for an earlier filing date under 35 U.S.C. § 120.